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Over the past decade, improvements in imaging technol-
ogies along with greater access to medical care have resulted
in the discovery of neoplasms in a much earlier stage. This
has contributed to a reduction in cancer mortality. However,
an unintended consequence of early detection has been detec-
tion of lesions which present at an earlier pathologic stage of
development, requiring modification of diagnostic criteria, as
well as determining a more appropriate risk stratification to
inform management.
The differential diagnosis between thyroid follicular epithe-
lial neoplasms was classically based on architectural arrange-
ment of either follicular or papillary growth. However, with
the 2004 World Health Organization (WHO) Classification of
Thyroid tumours (1), papillary carcinoma was defined by the
presence of characteristic nuclear features, including nuclear
crowding or overlapping, elongation, irregular contours,
grooves, and chromatin clearing, and thus these features
detected in a follicular-patterned neoplasm were diagnosed as
a follicular variant of papillary thyroid carcinoma (FV-PTC).
Interestingly, while capsular and/or lymphovascular invasion
were the defining criteria for classifying a well-differentiated
follicular neoplasm as follicular adenoma (no capsular nor
lymphovascular invasion) or follicular carcinoma (presence of
capsular and/or lymphovascular invasion), all epithelial neo-
plasms with the nuclear features of papillary carcinoma were
diagnosed as papillary carcinoma, regardless of whether the
neoplasms were encapsulated or invasive. Thus, distinctly
different from follicular neoplasms, all encapsulated follicu-
lar variant of papillary thyroid carcinoma were classified as
carcinomas (EFV-PTC), further subdivided based on the
presence or the degree of capsular and/or lymphovascular
invasion as invasive EFV-PTC or noninvasive EFV-PTC.
Noninvasive follicular thyroid neoplasm with papillary-
like nuclear features (NIFTP) is the new terminology pro-
posed for encapsulated follicular variant of papillary thyroid
carcinoma (EFVPTC) without evidence of capsular and/or
lymphovascular invasion.
Nikiforov et al. (2) reported the results of a histological
review of digitalized histologic slides from 210 cases with
thyroid nodules diagnosed as EFV-PTC by 24 experienced
endocrine pathologists from seven countries. During initial
evaluation, a very large group of histological variables was
used by members of the panel with not neglectable discrep-
ancies, even though all were expert thyroid gland pathol-
ogists. In a comprehensive and meticulous analysis, including
8 teleconferences and a face-to-face 2-day meeting, the members
reached a consensus on the nuclear features of papillary
thyroid carcinoma and defined the criteria for a noninvasive
EFV-PTC, reclassified as noninvasive follicular thyroid neo-
plasm with papillary-like nuclear features (NIFTP): Full
encapsulation or partial encapsulation with clear demarcation,
follicular growth pattern (o1% papillae) and the nuclear
features of papillary carcinoma, defined by a nuclear score
of 2 or 3 (see visual guide) as the necessary positive find-
ings. Further, exclusionary criteria were also developed: 1) the
absence of lymphovascular and capsular invasion in an
adequately sampled (i.e., completely submitted) tumor; 2) less
than 30% of the tumor volume showing a trabecular, insular or
solid architecture; 3) less than 3 mitoses/10 high power fields;
4) no necrosis identified; and 5) no psammoma bodies.
Employing these inclusion and exclusion criteria (see visual
guide) resulted in a high interobserver agreement, yielding a
sensitivity of 98.6% and specificity of 90.1% for non-invasive
EFV-PTC patients (109 patients followed for 10-26 years)
versus the invasive EFV-PTC patients (101 patients followed
for 1-18 years). This separation was important for clinical
purposes, as no patient from the noninvasive group devel-
oped any adverse event (no recurrence, no lymph node
metastasis, no distant metastasis), whereas 12% of the patients
from the invasive group developed some adverse event,DOI: 10.6061/clinics/2018/e576
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including distant metastases in five patients, leading to death
in two patients.
Molecular analysis for point mutations, gene fusions or
rearrangements detected in the clear majority of papillary
carcinomas were performed on 37 cases initially submitted
for inclusion into group 1 (noninvasive EFV-PTC) and on
26 new cases of EFV-PTC incorporated as a validation set.
Clonal molecular alterations were detected in 25 cases (68%),
with RAS mutations the most common. None of the 5 cases
excluded from the noninvasive group due to insufficient
nuclear features had any of these mutations. In contrast,
clonal mutations were detected in 21 (78%) of the lesions
remaining in this group. Based on this study, Nikiforov et al.,
(2) proposed that the noninvasive EFV-PTC should be
reclassified to noninvasive follicular thyroid neoplasm with
papillary-like nuclear features (NIFTP).
The immediate impact of that publication was likely due
to the multidisciplinary, international effort and systematic
review of the group of neoplasms by a large group of patho-
logy experts, which led to the relatively fast acceptance of the
terminology applied to a class of thyroid neoplasms that may
behave in a more indolent fashion than their fully malignant
counterparts, influencing clinical management and reducing
aggressive clinical treatments.
The 2017 WHO Classification of Endocrine Organ Tumours
(3) included NIFTP in the group of the so-called ‘‘follicular-
patterned neoplasms with borderline clinical behavior’’,
including NIFTP, along with follicular tumor of uncertain
malignant potential (FT-UMP) and well differentiated tumor
of uncertain malignant potential (WDT-UMP). While the
latter two tumors include ‘‘questionable capsular or lympho-
vascular invasion,’’ NIFTP lacks any invasion in a tumor
completely submitted for histological exam. The WHO clas-
sification also highlighted the strong association between the
RAS and other RAS-like mutations and NIFTP, distinctly
different from BRAF mutations frequently identified in other
subtypes of PTC (3).
Within a year of publication, several series from different
countries have been published, further corroborating and
supporting the initial findings of a very low malignant poten-
tial tumor, without recurrence or metastasis.
Thompson (4) reviewed 94 cases of EFVPTC measuring
0.7 to 9.5 cm in diameter, with a mean tumor size of 3.3 cm,
reviewing an average of 11.9 slides per cases. Capsular and/
or lymphovascular invasion was found in 17 and no invasion
in 77 cases. Lobectomy or thyroidectomy was the initial
treatment combined with post-op radioablative iodine in
25 patients. Without any recurrence and no lymph node or
distant metastases after a median follow-up of 11.8 years,
Thompson concluded that encapsulated follicular variant of
papillary thyroid carcinoma could be treated by conservative
surgery alone and could be accurately reclassified as NIFTP
based on the inclusion and exclusion criteria published.
Reviewing their series of 860 PTC 41.0 cm from Brazil,
Rosario et al. (5) identified 129 cases which fulfilled the
criteria for NIFTP, representing about 15% of all PTC cases.
Based on original diagnoses, none of the patients reclassified
as NIFTP had been given radioactive iodine therapy.
No patient developed recurrence or metastasis during the
median follow-up period of 72 months (range 12-146 months).
In an evaluation of large neoplasms exclusively (44 cm),
Xu et al. (6) showed that all 79 patients with NIFTP were
without lymph node or distant metastases, including 25 patients
managed without radioablation, followed for a median of
11.2 years. Furthermore, Rosario et al. (7) recently reported a
favorable clinical course in 45 patients with NIFTP larger
than 4 cm, where there was only 1 patient who developed
lymph node metastasis, but this patient had a concurrent
microscopic papillary carcinoma in addition to the NIFTP.
By contrast, not all recent reports show a completely
benign clinical course, validating the classification of this
lesion as a borderline or low grade tumor as proposed by
Nikiforov et al. (2) and further endorsed by the WHO (3).
Reviewing of 4,790 PTCs from Canada, Parente et al. (8)
identified 102 cases using strict criteria for NIFTP (2.1% of all
PTCs). Although the overall clinical behavior was favorable,
5 of the 102 patients (4.9%) presented lymph node metastasis
and one case had a distant metastasis (8).
Kim et al. (9) studied 74 NIFTPs from Korea and identified
lymph node metastasis in 9 (12%). However, 5 of their 9 cases
had coexisting PTCs (9), and thus this number may not be
representative.
Cho et al. (10) assessed the impact of finding a minor per-
centage of true papillae mixed with the neoplastic follicles in
a cohort of 152 EFV-PTCs. Of this group, 105 cases had isolated
papillae, but stillo1% as defined by criteria for invoking the
diagnosis of NIFTP; 3 (3%) patients presented with central
lymph node metastasis, 1 (1%) patient had distant metas-
tasis, while at a molecular level, 10 (10%) of the tumors
showed BRAF V600E mutation. If the stricter criterion of no
papillae was applied, all cases with BRAF V600E mutation
were eliminated, leaving 95 cases without invasion, but still
2 (3%) patients had central lymph node metastasis (10).
The authors of this editorial, written on behalf of the
members of the NIFTP working group (2), wish to reiterate
that the histological criteria for NIFTP must be strictly
adhered to in order to keep this category as pure as possible,
undiluted by more classical papillary carcinomas that show a
characteristic fully malignant potential. Specific considera-
tion must be given to the following criteria:
a. Presence of papillae: Although the original concept was
that some isolated hyperplastic-type papillae could be
accepted, the criterion of o1% of papillae was used to
highlight how limited the papillary structures should be.
It appears that this criterion has been misinterpreted and
expanded to allow well-formed papillary structures to be
present. Thus, we believe that this exclusion criterion should
be modified to state that ‘‘no true papillary structures’’ are
acceptable for diagnosing NIFTP. When papillae are present,
another diagnosis (such as encapsulated noninvasive PTC
or classical PTC) would be more appropriate.
b. Fully-developed nuclear features of PTC: When using the
visual guide (Figure 1), a nuclear score of 2 or 3 was
required for the diagnosis of NIFTP. However, in wide-
spread clinical application, it is important to realize that
most cases of NIFTP show a nuclear score of 2 rather
than 3. Thus, if the case has florid nuclear features of
papillary carcinoma (i.e., nuclear score of 3), additional
effort should be undertaken to be certain there are no
papillae or invasion. This should include examination of
the entire capsule and also the whole tumor.
c. Sufficient sections submitted: Review of the cases received
in consultation since the introduction of NIFTP has demon-
strated many cases without a full representation of the
tumor-to-capsule-to-parenchymal interface. Unless more sec-
tions to include the entire periphery of the tumor can be
submitted, we recommend not to diagnose NIFTP, and
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instead render a diagnosis of EFVPTC. The entire capsule
should be examined to confirm this diagnosis. To exclude the
presence of a papillae, the entire lesion must be examined.
d. Molecular characteristics: Definitive molecular profiles for
various papillary and follicular neoplasms are not unique
nor well developed at present. Thus, NIFTP shows an
overlapping molecular signature with other neoplasms.
While research on micro-RNA expression and other molec-
ular findings are ongoing, if molecular studies have been
performed, and mutations characteristic of conventional
PTC or high-risk cancer are identified, such as BRAF
V600E, RET/PTC, or TERT the diagnosis of NIFTP should
not be made. The typical molecular profile of NIFTP is of
RAS and other RAS-like mutations, and thus other mole-
cular findings may be used to exclude the diagnosis of
NIFTP.
In conclusion, we would like reiterate that when appropri-
ately diagnosed, NIFTP is a borderline entity with indolent
clinical behavior. However, the histological criteria for NIFTP
should be strictly followed in order to keep this category as
pure as possible.
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